Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanofi IndiaBOM:500674 -0.54%77 ROA % is 32.71% as of Mar. 2026, which is 71% above its 10-year median of 19.15. GuruFocus rates BOM:500674 with a GF Score™ of 77/100 and a GF Value™ of ₹4,402.68 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Sanofi India ranks better than 96.92% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sanofi India's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹4,104 Mil.
Sanofi India's average Total Assets over the quarter that ended in Mar. 2026 was ₹12,548 Mil. Therefore, Sanofi India's annualized ROA % for the quarter that ended in Mar. 2026 was 32.71%.
The historical rank and industry rank for Sanofi India's ROA % or its related term are showing as below:
BOM:500674'
s ROA % Range Over the Past 10 Years
Min: 12.26 Med: 19.15 Max: 31.84
Current: 22.64
During the past 13 years, Sanofi India's highest ROA % was 31.84%. The lowest was 12.26%. And the median was 19.15%.
BOM:500674's ROA % is ranked better than 96.92% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.73
vs BOM:500674: 22.64
Sanofi India (BOM:500674) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Sanofi India ROA % Related Terms
Sanofi India ROA % Historical Data
* Premium members only.
The historical data trend for Sanofi India's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Sanofi India's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi India ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi India's ROA % distribution charts can be found below:
* The bar in red indicates where Sanofi India's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Sanofi India (BOM:500674) has a ROA % of 32.71% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sanofi India and its competitors. This is 71% above median its historical median of 19.15. Over the past decade, Sanofi India's ROA % has ranged from 12.26 to 31.84. According to the industry distribution chart, Sanofi India ranks #31 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 3.1%.
Is Sanofi India's ROA % too high?
Sanofi India's current ROA % of 32.71% is 71% above median its 10-year median of 19.15. Over the past 10 years, this metric has ranged from a low of 12.26 to a high of 31.84. The Drug Manufacturers industry median ROA % is 2.73. Sanofi India's value of 32.71% is 1098.2% above this industry median. Based on the distribution chart, Sanofi India ranks #31 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi India has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi India ranks #31 out of 1008 companies for ROA %. This places Sanofi India in the top 3% of its industry — outperforming the majority of peers. The industry median ROA % is 2.73. Sanofi India's value of 32.71% is 1098.2% above this benchmark. Historically, Sanofi India's own ROA % has ranged from 12.26 to 31.84 over the past decade. While the company's 10-year median is 19.15 vs. the industry median of 2.73, Sanofi India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.73, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi India's current ROA % of 32.71% is 1098.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sanofi India and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi India's current ROA % is 32.71%, which is 71% above median its own 10-year median of 19.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,402.68, compared to a current price of ₹3,369.25 — trading 23.5% below its estimated fair value. The current ROA % is 32.71%, which is 71% above median its 10-year median of 19.15 and 1098.2% above the Drug Manufacturers industry median of 2.73. Sanofi India's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current ROA % is 32.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi India (BOM:500674) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued.
The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,402.68.
GuruFocus considers Sanofi India to be Modestly Undervalued.
Key valuation signals for BOM:500674:
ROA %: 32.71% (71% above median its 10-year median of 19.15)
GF Value™: ₹4,402.68 vs. price of ₹3,369.25 (23.5% below fair value)
Industry Position: 1098.2% above the Drug Manufacturers median (#31 of 1008)
No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score
Get the complete analysis for BOM:500674
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500674 has been successfully added to your 
